

1 **Induction of robust neutralizing antibodies against the COVID-19 Delta variant with**
2 **ChAdOx1 nCoV-19 or BNT162b2 as a booster following a primary vaccination series with**
3 **CoronaVac**

4
5 Samadhi Patamatamkul¹, Sutthiwan Thammawat¹, Benjaporn Buranrat²

6
7 ¹Faculty of Medicine, Mahasarakham University, Muang District, Maha Sarakham, 44000,
8 Thailand

9 ²Biomedical Sciences Research Unit, Faculty of Medicine, Mahasarakham University, Muang
10 District, Maha Sarakham, 44000, Thailand

11
12 Running title

13 Neutralizing antibody after the third booster

14
15 *Corresponding author name and full mailing address

16 Samadhi Patamatamkul, M.D.
17 Department of Medicine, Faculty of Medicine, Mahasarakham
18 University 44000, Bangkok, Thailand
19 Tel +66815441374. Email address: samadhi.p@msu.ac.th

20
21 E-mail:
22 sutthiwan.t@msu.ac.th
23 benjaporn.b@msu.ac.th

24
25 Word count: 1,011 including references

26
27
28
29
30
31

32

33 **Abstract**

34

35 We determined the antibody response among CoronaVac vaccinees who were boosted
36 with either BNT162b2 or ChAdOx1 nCoV-19. Increase in anti-S-RBD antibodies and surrogate
37 neutralizing antibodies against the Delta variant was higher in BNT162b2 recipients than in
38 ChAdOx1 nCoV-19 recipients. High proportions of reactogenicity were seen for both booster
39 regimens.

40

41 **Keywords:** Neutralizing antibody, COVID-19 vaccination, third booster

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63 As the COVID-19 Delta variant spreads globally, COVID-19 breakthrough infections are
64 increasing despite primary COVID-19 vaccination being completed. In Thailand, most
65 healthcare personnel have been vaccinated with an inactivated virus vaccine, CoronaVac
66 (Sinovac Biotech, Beijing, China). A recent viral neutralization test (VNT) of CoronaVac
67 vaccinees in the Thai population demonstrated markedly reduced titers against the Delta variant
68 as compared to convalescent sera [1]. Therefore, a booster dose of either ChAdOx1 nCoV-19 or
69 BNT162b2 was voluntarily administered to healthcare personnel in Thailand in July–August
70 2021 as per national policy. Here, we examined the immunogenicity and reactogenicity among
71 healthcare personnel before and after CoronaVac and the third booster dose.

72 We prospectively enrolled 41 healthcare personnel from Suddhavej Hospital,
73 Mahasarakham University, Mahasarakham, Thailand, for longitudinal collection of blood
74 samples (pre-vaccination, post-second CoronaVac, pre-booster, post-booster) during April to
75 August 2021. All participants were seronegative for anti-S-RBD (spike protein receptor-binding
76 domain) and anti-nucleocapsid antibodies before COVID-19 vaccination, and had not been
77 previously diagnosed with COVID-19 infection.

78 We used Elecsys Anti-SARS-CoV-2 \square S (Roche Diagnostics GmbH, Mannheim,
79 Germany) and a cPass™ SARS-CoV-2 NAbs Detection Kit as a surrogate VNT (sVNT)
80 (GenScript, Piscataway, NJ, USA) to examine immunogenicity. The sVNT uses a SARS-CoV-2
81 spike protein (RBD, L452R, T478K, Avi & His Tag)-HRP reagent, which is specific for the
82 Delta variant S-RBD. The sVNT protocol followed the manufacturer's instructions, with a 30%
83 inhibition cutoff described elsewhere [2].

84 Of the 41 participants, 23 received BNT162b2 as the booster dose. Age and gender did
85 not differ significantly among the ChAdOx1 nCoV-19 and BNT162b2 recipients: 38 ± 10.26 vs.
86 32.04 ± 3.42 years ($p = 0.188$); 66.7% vs. 60.9% female ($p = 0.702$). One participant per group
87 had pre-existing diabetes mellitus.

88 The post-second CoronaVac and pre-booster sera anti-S-RBD antibody levels did not
89 differ significantly: 64.72 U/mL (interquartile range [IQR], 22.23–188.86) vs. 106.8 U/mL (IQR,
90 49.89–151.7) ($p = 0.270$) for ChAdOx1 nCoV-19, and 37.78 U/mL (IQR, 16.79–73.8) vs. 37.46
91 U/mL (IQR, 23.39–51.60) ($p = 0.932$) for BNT162b2. Anti-S-RBD-antibodies were significantly
92 higher after booster vaccination with BNT162b2 rather than with ChAdOx1 nCoV-19: 22,558
93 U/mL (IQR, 15,956–25,000) vs. 5,159 U/mL (IQR, 3,647.75–9,196.75) ($p < 0.001$) (Figure 1A).

94 Up to 65.7% of CoronaVac vaccinees in the whole cohort achieved sVNT \geq 30%
95 inhibition, as did 64.3% and 66.7% of ChAdOx1 nCoV-19 and BNT162b2 recipients,
96 respectively. The proportions of participants who maintained pre-booster sVNT \geq 30% inhibition
97 decreased significantly after the second CoronaVac shot: 65.7% (95% confidence interval [CI],
98 49.1–79.2) to 12.9% (95% CI, 4.5–29.5) ($p < 0.001$). After the booster shot, this increased to
99 100% (95% CI, 89.8–100) ($p < 0.001$). The median sVNT from after the second CoronaVac to
100 before the booster shot significantly declined: 37.67% (IQR, 25.58–61.54) to 18.71% (IQR,
101 9.66–20.98). It increased after boosting to 97.52% (IQR, 96.72–98.03) (Figure 1B). BNT162b2
102 recipients had higher sVNT than ChAdOx1 nCoV-19 recipients: 97.76% (IQR, 97.5–98.29) vs.
103 97.02% (IQR, 93.8–97.64), respectively ($p < 0.001$; Figure 1C).

104 Anti-S-RBD antibodies correlated with the sVNT value (Spearman correlation coefficient
105 of 0.82; 95% CI, 0.75–0.88) ($p < 0.001$). At anti-S-RBD antibody levels of \geq 583 U/mL, the
106 sensitivity, specificity, positive predictive value, and negative predictive value for sVNT \geq 68%
107 were 83.1%, 100%, 100%, and 85.5%, respectively.

108 The median time between collection of post-second CoronaVac sera and pre-booster sera
109 was not significantly different between the two groups: 4 weeks (IQR, 3–5.25) vs. 4 weeks (IQR,
110 3–4) for ChAdOx1 nCoV-19, and 11 weeks (IQR, 10–12) vs. 12 weeks (IQR, 11.75–12) for
111 BNT162b2. The median time between the booster dose and serum collection was 3 weeks (IQR,
112 2.75–3) vs. 2 weeks (IQR, 2–2), respectively ($p < 0.001$).

113 All participants had at least one symptom after the booster (Table 1). Up to 92.5% of
114 participants used acetaminophen for relieving symptoms.

115 This is the first prospective study of a booster dose with viral vector or mRNA vaccine
116 after CoronaVac vaccination in the Thai population. Our findings demonstrate a robust antibody
117 response in terms of both anti-S-RBD antibodies and sVNT after boosting with ChAdOx1
118 nCoV-19, and even more so with BNT162b2. All participants achieved more than 68%
119 inhibition against the Delta variant, which is the cutoff for high-titer neutralizing antibodies
120 according to the US-FDA. Our findings are concordant with the mouse model, where a
121 heterologous vaccine booster with either viral vector or mRNA vaccine after completion of the
122 primary regimen with an inactivated vaccine significantly increased the levels of neutralizing
123 antibodies [3].

124 With regard to CoronaVac durability, we found that only 12.9% maintained sVNT at
125 above the cutoff after 3 months. Our findings are concordant with the previous study regarding
126 the persistence of anti-spike antibodies with decreasing neutralizing effect [4].

127 We found overall higher reactogenicity in our cohort than previously reported with
128 BNT162b2 or ChAdOx1 nCoV-19 [5].

129 In conclusion, after CoronaVac primary vaccination, both BNT162b2- and ChAdOx1
130 nCoV-19-boosted recipients demonstrated consistently high neutralizing antibodies against the
131 Delta variant. BNT162b2 may be a more favorable booster, with significantly higher neutralizing
132 antibodies, which may correlate with better clinical effectiveness.

133

134 **Funding source**

135 This work was supported by the Faculty of Medicine, Mahasarakham University.

136

137 **Conflicts of interests**

138 The authors declare no conflicts of interest.

139

140 **Acknowledgements**

141 We thank all the laboratory technicians who helped with the sample collection throughout
142 the study.

143

144 **Ethical approval**

145 The Mahasarakham University Ethics Committee approved the study. Informed consent
146 was obtained before blood collection.

147

148 **References**

- 149 1. Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T,
150 Ludowyke N, et al. CoronaVac induces lower neutralising activity against variants of
151 concern than natural infection. *Lancet Infect Dis* 2021. [https://doi.org/10.1016/S1473-3099\(21\)00568-5](https://doi.org/10.1016/S1473-3099(21)00568-5).
152
- 153 2. Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, et al. A SARS-CoV-2 surrogate
154 virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-

- 155 protein interaction. *Nat Biotechnol* 2020;38:1073–8. [https://doi.org/10.1038/s41587-020-](https://doi.org/10.1038/s41587-020-0631-z)
156 [0631-z](https://doi.org/10.1038/s41587-020-0631-z).
- 157 3. Zhang J, He Q, An C, Mao Q, Gao F, Bian L, et al. Boosting with heterologous vaccines
158 effectively improves protective immune responses of the inactivated SARS-CoV-2
159 vaccine. *Emerg Microbes Infect* 2021;10:1598–608.
160 <https://doi.org/10.1080/22221751.2021.1957401>.
- 161 4. Widge AT, Roupheal NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al.
162 Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *N Engl J Med*
163 2021;384:80–2. <https://doi.org/10.1056/NEJMc2032195>.
- 164 5. Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, et al. Safety,
165 reactogenicity, and immunogenicity of homologous and heterologous prime-boost
166 immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
167 *Lancet Respir Med* 2021. [https://doi.org/10.1016/S2213-2600\(21\)00357-X](https://doi.org/10.1016/S2213-2600(21)00357-X).

168

169 **Authors' contributions**

170 SP: Designed the study, interpreted the findings, and wrote the paper.

171 BB: Performed the laboratory experiments and interpreted the findings.

172 ST: Performed the laboratory experiments and interpreted the findings.

173

174

175

176

177

178

179

180

181

182

183

184

185

186 **Figure legends**

187 **Figure 1.** (A) Longitudinal changes in anti-S-RBD antibodies before and after CoronaVac and
188 after booster between BNT162b2 and ChAdOx1 nCoV-19 recipients are shown as separated
189 scatter with bars. The positive cutoff value at ≥ 0.8 U/mL denotes reactive anti-S-RBD
190 antibodies. Error bars represent the median and IQR. (B) Scatter plots demonstrate longitudinal
191 changes in sVNT in the whole cohort. Dashed lines represent the median. (C) Scatter plots with
192 each replicate connected show longitudinal changes in sVNT between BNT162b2 and ChAdOx1
193 nCoV-19 recipients; $\geq 30\%$ inhibition denotes significant inhibition of the Delta variant. $P \leq 0.05$
194 (two-sided) denotes a significant difference using non-parametric Friedman's two-way analysis
195 with Bonferroni correction for multiple tests. All statistical analyses were performed with SPSS
196 28 (IBM Corp., Armonk, NY, USA).

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217 **Table legends**

218 **Table 1.**

219 † One participant had peripheral bilateral numbness of the hands, achieving recovery after 1-
220 week gabapentin; another had acute tonsillitis requiring antibiotics.

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248 **Figures**

249 Figure 1

250

251 A

252

253

254

255

256

257

258

259


260

261

262

263

264



265 B

266

267

268

269

270

271

272

273


274

275

276

277

278



279 C

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304


305

306

307

308

309



310 **Tables**

311 **Table 1** Proportions of reactogenicity in each group

	ChAdOx1 nCoV-19	BNT162b2	P-value
Pain at injection site (%)	77.8	91.3	0.377
Fever (%)	66.7	39.1	0.080
Myalgia (%)	66.7	65.2	0.923
Headache (%)	38.9	13.0	0.075
Chills (%)	50.0	21.7	0.058
Nausea and/or vomit (%)	11.1	26.1	0.429
Rash (%)	5.6	0	0.439
Weakness (%)	5.6	4.3	1
Symptoms requiring medications (%)	94.4	91.3	1
Others (%)	0	8.7†	0.243
Duration of symptoms (median, IQR)	2 (1–3)	3 (2–3)	0.139

312

